Title: Artificial Intelligence in Regenerative medicine-Stem Cells Applications and Implication.
Abstract: The field of regenerative medicine is constantly advancing and aims to repair, regenerate, or substitute impaired or unhealthy tissues and organs using cutting-edge approaches such as stem cell-based therapies, gene therapy, and tissue engineering.
These cells have the potential to multiply and specialize into diverse tissues, as well as the capacity to self-renew. It is being researched to treat an array of conditions, including autoimmune, metabolic, congenital, cardiovascular, musculoskeletal, and liver illnesses that cannot be fully managed by existing drugs. Before the entire potential of stem cell and regenerative medicine can be realized, there are still obstacles and limitations that must be overcome, particularly in the areas of technology, society, regulation, and ethics.
Artificial intelligence (AI) is rapidly advancing, aiming to mimic human cognitive abilities, and is addressing complex medical challenges in the field of biological science. Over the past decade, AI has experienced exponential growth and proven its effectiveness in processing massive datasets and optimizing decision-making. The incorporation of artificial intelligence (AI) is crucial and useful for overcoming these challenges.
Using an AI-driven manufacturing technique can aid in determining stem cells' sustainability, performance, efficacy, and safety before they are supplied to patients. It can also offer an improved framework for figuring out the best conditions for the growth of stem cells. Additionally, AI could deal with the intricate situations in regenerative therapy that might be susceptible to mistakes related to human error.
Artificial intelligence has the potential to make significant advances in disease risk prediction, diagnosis, prognosis, and treatment and to reshape the future of healthcare.
BIO: Prof. Vasiliki E. Kalodimou is the Assistant Professor and the former acting Chair, at the European University-Cyprus Ltd. Frankfurt Branch, collaborative Partner for the Greek Research Infrastructure for the visualization and monitoring of fundamental Processes in Biology and Medicine (BIOIMAGING-GR) at NCSR "DEMOKRITOS", Athens-Greece, the collaborative partner for training and research for Regenerative Medicine Program at the Institute of Personalized Molecular Medicine at the Medical City Hospital, Philippines, the Board/Committee on Research Ethics at the National Hellenic Research Foundation (Ε.Ι.Ε), she elected to serve as the Vice-Chair of the UEL Alumni Advisory Board, previously was the t Director at the Flow Cytometry-Research and Regenerative Medicine Department of IASO Maternity-Pediatric and Research Hospital in Athens, Greece and the CBB Director & Processing Facility Director at MedStem-Cryobanks of IASO. Before her current appointment, Kalodimou served as a hematology research associate at General University Hospital of Heraklion, Crete, and as an instructor at both the General University Hospital of Heraklion and the Ipokratios Medical-Technical Institute of Athens.
Since 2006, Dr. Kalodimou has studied and working with stem cells from placenta, umbilical cord and adipose tissue, in every day practice and their applications in regenerative medicine, clinical trials, medical tourism and Flow Cytometry. Also is working in the area of human genetics & population genetics, soluble vitamins and stem cells and their role in human health, stem cells organ 3D printing as well as cellular standards.
In addition to collaboration with state universities and pharmaceutical companies on research projects (20), Kalodimou frequently publishes (49 & 12 books) her findings. She has 2 patents and many awards globally as an expert in biotherapies.
She is a experience mentor for biotherapies and also she is in the editorial board and a reviewer in several scientific international journals as well as board member in scientific organizing committee’s for medical conferences worldwide.